Tactiva Therapeutics

Founded in 2016 and headquartered in Buffalo, US, Tactiva Therapeutics specializes in advanced cancer treatment strategies.Tactiva Therapeutics specializes in innovative cancer immunotherapy, focusing on the development of advanced adoptive cell therapy (ACT) strategies. The company’s primary product offerings involve a dual T cell receptor (TCR) platform that utilizes both CD4 and CD8 T cells reprogrammed to recognize and attack cancer cells. This approach enhances the anti-tumor efficacy by leveraging the synergistic effects of these two T cell types, potentially leading to sustained tumor control and durable remission for patients. Tactiva’s therapies aim to address a range of solid tumors and are tailored for patients undergoing cancer treatment, including those with advanced-stage cancers.The revenue structure of Tactiva Therapeutics is based on the provision of advanced cancer immunotherapy solutions through direct partnerships and collaborations with healthcare institutions and oncology centers. Transactions occur through contracts for the application of their T cell therapy products in clinical settings, potentially involving one-time fees or ongoing treatment agreements. The company's flagship offerings, centered around its engineered T cells bearing proprietary TCRs, may be integrated into broader oncology treatment regimens. This model supports a B2B approach, where healthcare providers implement Tactiva’s therapies as part of their cancer treatment protocols, contributing to the firm's revenue stream. The company also intends to expand its presence in North America and Europe, focusing on establishing partnerships with additional healthcare providers by late 2023.

1. Series A

   Dec 3, 2018

   Amount

   $35M

   Investors

   Locked